Abundance Potential

Assessment scope

Development

A centralized operational hub coordinating home based interventions in multisite clinical trials, including equipment, onboarding, remote supervision, adherence monitoring, and recovery.

Baseline

Conventional multisite trial delivery in which participating sites independently deliver interventions.

Population

People participating in multisite trials, especially those facing geographic, mobility, or scheduling barriers to repeated in person visits; broader populations and people with higher disability or caregiver dependence are not established by this trial.

Geography

United States; the described implementation covered 22 trial sites.

Target assumptions

The potential assessed is the hub's contribution to trial access and research capability, not clinical benefit from the interventions. Broader benefit assumes comparable staffing, equipment, connectivity support, and operational coordination. The supplied source is a bounded beginning and end excerpt; omitted content is unknown.

Five dimensions

Human wellbeing

Unknown · This operational report does not establish whether the interventions improved participants' symptoms or other health outcomes. Sources: evidence-1991

Affordability and access

2/4 · Remote delivery coordinated participants across 22 U.S. sites, and the report describes providing hotspots and prepaid data to participants without reliable internet. This supports a meaningful but bounded access contribution; the model still required dedicated staff, equipment, and technical support, and comparative costs were not measured. Sources: evidence-1988, evidence-1992, evidence-1991

Reach and fairness

1/4 · A hub coordinated remote interventions across multiple sites and the source identifies geographic and mobility barriers that remote participation may address. Evidence is limited to one trial; it does not establish equitable reach across populations, and the source notes that participants had sufficient technology access and support to complete procedures. Sources: evidence-1988, evidence-1991

Environment and resources

Unknown · The report does not measure environmental effects, resource use, or cost effectiveness; it describes equipment shipping and dedicated operational support without quantifying their net resource impact. Sources: evidence-1991, evidence-1993

Scientific capability

2/4 · The hub demonstrated operational feasibility for coordinating several remote intervention types across 22 sites, with up to 168 participants active concurrently. This is a meaningful but bounded contribution to multisite trial capability; scalability, comparative advantage, implementation fidelity, and reproducibility remain unestablished. Sources: evidence-1988, evidence-1989, evidence-1991, evidence-1992

Evidence, confidence and timing

Evidence maturity

Finding: Deployed. The hub was implemented in one phase 2 trial, coordinating remote intervention delivery across 22 U.S. sites and supporting up to 168 participants concurrently. This establishes deployment in that trial context, not general scalability.

Societal benefit: Prototype pilot. Access and research-capability benefits are plausible from this single trial implementation, but the report does not compare delivery models, measure costs, or establish broader societal outcomes.

Confidence: Low. Operational results are reported for one descriptive trial, while comparative delivery performance, costs, staffing demands, fidelity, generalizability, and clinical benefit are not established. Confidence in broader societal benefit is therefore low.

Conditional time horizon: Medium (5–15 years). Broader benefits depend on replication and assessment of staffing, resource use, and performance in other trial settings; the source identifies these as future work, so wider effects are conditional and may take 5–15 years.

Possible benefits

• Remote coordination may make trial participation more accessible to people facing geographic, mobility, or scheduling barriers, provided the required technology and support are available. Sources: evidence-1988, evidence-1991
• A centralized hub may support standardized coordination of multiple remote interventions across distributed trial sites and inform future decentralized or hybrid trial designs. Sources: evidence-1988, evidence-1992

Risks and possible harms

• The model depends on dedicated staffing, equipment, connectivity, and logistical support; without comparable resources, implementation may be less accessible or sustainable. The report did not measure costs or staff effort. Affected groups: Trial participants without reliable internet or equipment access; trial sites and health systems with limited staffing or technical resources. Sources: evidence-1991, evidence-1992
• The report does not establish treatment effectiveness or clinical benefit, so operational feasibility should not be taken as evidence that participants' health improves. Affected groups: People with cognitive symptoms associated with long COVID and other prospective trial participants. Sources: evidence-1991

Distribution and adoption

Who might be excluded

• The source says participants had sufficient access to technology and remote support to complete procedures, and calls for future studies to include people with higher levels of disability and those who are caregiver dependent; their access and outcomes are not established here. Sources: evidence-1991

Adoption barriers

• Replication requires technical and staffing infrastructure, equipment preparation and shipping, participant onboarding, remote supervision, and technical support; the trial's performance does not establish cost, staffing requirements, or scalability. Sources: evidence-1991, evidence-1992, evidence-1989

Assumptions and conditions that could change the assessment

• Potential access gains extend beyond the observed trial only if other settings can provide comparable staffing, devices, connectivity support, and coordination. Sources: evidence-1991, evidence-1992
• The assessment concerns the operational hub's potential contribution to access and research capability; it does not assume clinical effectiveness of the trial interventions. Sources: evidence-1991
• Evidence of reproducible performance across different populations and trial settings, with measured staffing, costs, resource use, fidelity, and outcomes, could support higher confidence and revised access or capability scores. Sources: evidence-1991
• Evidence that the model fails to reach participants with limited technology access, higher disability, or caregiver dependence, or that required resources are unsustainable, could lower access and fairness assessments. Sources: evidence-1991

Citations

1. evidence-1988 · A central hub model for remote delivery of multisite clinical trial interventions · L; e; i; g; h; ; C; h; a; r; v; e; t · 10.1371/journal.pdig.0001818 · Captured publisher article text · Open source
2. evidence-1989 · A central hub model for remote delivery of multisite clinical trial interventions · L; e; i; g; h; ; C; h; a; r; v; e; t · 10.1371/journal.pdig.0001818 · Captured publisher article text · Open source
3. evidence-1991 · A central hub model for remote delivery of multisite clinical trial interventions · L; e; i; g; h; ; C; h; a; r; v; e; t · 10.1371/journal.pdig.0001818 · Captured publisher article text · Open source
4. evidence-1992 · A central hub model for remote delivery of multisite clinical trial interventions · L; e; i; g; h; ; C; h; a; r; v; e; t · 10.1371/journal.pdig.0001818 · Captured publisher article text · Open source
5. evidence-1993 · A central hub model for remote delivery of multisite clinical trial interventions · L; e; i; g; h; ; C; h; a; r; v; e; t · 10.1371/journal.pdig.0001818 · Captured publisher article text · Open source